Analysis of cancer risk in primary immune deficiency (PID) offers insight into the relationship between immune function and cancer. Data on Australian patients (n = 1132) notified voluntarily to the Australasian Society of Clinical Immunology and Allergy PID Registry (1990-2008) were linked with national death and cancer registries. Person-years of follow-up commenced from up to 15 years before registration on the PID Registry or January 1982, the inception of national cancer registration. Site-specific, 5-year age-, sex-, calendar year–, and state-standardized incidence ratios (SIRs) with 95% confidence intervals (95% CIs) were calculated for all cancers except nonmelanocytic skin cancer. During an average of 16 person-years follow-up, a 1.6-fold excess relative risk of cancer was observed (n = 58; SIR 1.60, 95% CI 1.22-2.07) for all PID combined. Relative risk was increased for non-Hodgkin lymphoma (n = 16; SIR 8.82, 95% CI 5.04-14.30), leukemia (n = 4; SIR 5.36, 95% CI 1.46-13.73), and stomach cancer (n = 3; SIR 6.10, 95% CI 1.26-17.84). Excess cancer risk was observed for predominantly antibody deficiencies and other well-defined immunodeficiency syndromes. Results suggest that predominantly antibody deficiencies may be associated with a narrower range of solid cancers than immunodeficiency characterized by predominantly T-cell deficiency, such as iatrogenic and HIV-related immunodeficiency, although this requires confirmation in larger cohorts.

The contribution of immune dysfunction to cancer risk is receiving increasing attention. Recent findings from population studies in people with HIV and solid-organ transplantation have uncovered a quantifiable contribution of immune deficiency to cancer risk.1  They suggest that predominantly T-cell deficiency is associated with an increased risk of a wide range of cancers, in particular cancers with a known or suspected infectious etiology. Examinations of immune-related and other risk factors in these cohorts have suggested that impairment of individual immune effector pathways may influence the risk of specific cancers.2-6  Studies of the cancer profile and risk determinants in primary immune deficiency (PID) have the potential to provide further insight.

PID comprises more than 150 distinct entities caused by genetic defects that primarily affect specific functional immunity.7  PID has been associated with a markedly increased risk of cancer, in particular non-Hodgkin lymphoma (NHL).8-13  However, the PID cancer risk profile is not well characterized because most previous studies have been nonpopulation-based, of small sample size, of limited follow-up, and without a matched comparison group. Other cancers that appear to be associated with specific forms of PID include stomach cancer with common variable immune deficiency (CVID),8,11  leukemia with ataxia-telangiectasia (AT),10,13  and nonmelanocytic skin cancer with cartilage-hair hypoplasia.12  Here, we report the overall and site-specific incidence of cancer relative to the general population for a national cohort of Australians with a diverse range of PID, a majority with predominantly antibody deficiencies.

Study population

The study included Australian children and adults diagnosed with PID, as notified to the Australasian Society of Clinical Immunology and Allergy (ASCIA) PID Registry 1990 to February 1, 2008. The ASCIA Registry receives voluntary case notifications for 56 separate PID syndromes from 79 centers across Australia but does not perform active follow-up or ascertain treatment data.14,15 

Data collection

Incident deaths were ascertained by the use of data linkage with the Australian National Death Index. The Index records all deaths in Australian residents, as reported to each of the jurisdictional registers of births, deaths, and marriages, since 1980. Incident cancers were ascertained by the use of data linkage with the Australian National Cancer Database, a compilation of data on all incident primary invasive cancers (except nonmelanoma skin cancer, C44) diagnosed in Australian residents from January 1, 1982 to December 31, 2005. Registration of such cancers is mandated throughout Australia. Polymorphic lymphoproliferative disorders (International Classification of Diseases for Oncology, 3rd edition [ICDO-3] 9970/1) were not included because they are not routinely registered by Australian cancer registries. Data linkage was determined by patient name code, sex, date of birth, and date of death (if deceased) by the use of a customized algorithm and clerical review rules.16,17  For each matched record, the date of cancer diagnosis and the topography and morphology codes were obtained (ICDO3, International Classification of Diseases, 10th revision [ICD-10]). Site-specific general population cancer rates were also obtained by 5-year age, sex, state, and calendar year from 1982 to 2005.

The ASCIA Registry is approved to collect data on the first 2 letters of the first and last name of each patient, as well as the date of birth and sex, enabling probabilistic data linkage. Ethical approval for data linkage was obtained from all relevant institutional ethics committees. The requirement for informed consent from patients was waived because the researchers received only deidentified data.

Statistical analysis

A congenital basis for PID, and therefore immune dysregulation from birth, was assumed for all patients. This assumption extended the person-years (PYs) of follow-up for cancer by adding a retrospective time period (up to 15 years) before the date of ASCIA registration. Thus, PYs at risk of cancer were accumulated from January 1, 1982 (commencement of the Australian National Cancer database), the date of birth, or 15 years before the ASCIA registration date, whichever occurred last, until the date of cancer diagnosis, death, or December 31, 2005. The retrospective PYs were survival-adjusted to account for those with PID who may have developed cancer and died before registration in the ASCIA Registry. The maximum duration of the retrospective period was determined by the available period-specific cancer survival rates (1 to 15 years). Australian national (1982-1997) or South Australian (1977-1998) population-based survival rates were used, these being the most comprehensive available.18,19  Specifically, PYs were adjusted by applying the period-specific, all-age, sex-, and site-specific cancer survival rates up to 15 years before ASCIA registration. This approach has been used in other registry-based linkage studies involving retrospectively defined follow-up periods.16,20-22  Cancers were classified according to ICD-10, with the exception of Kaposi sarcoma and lymphoid and hematopoietic neoplasms, which were classified according to ICDO-3 morphology codes.23 

Standardized incidence ratios

The ratio of the observed to the expected numbers of cancers, the standardized incidence ratio (SIR), was calculated with exact 95% confidence intervals (95% CIs). The expected numbers of cases were computed on the basis of the general population cancer incidence rates, assuming a Poisson distribution.24  “All cancer” and site-specific cancer SIRs were calculated for the entire cohort, separately for men and women, and also for children (< 16 years of age) and adults.

“All cancer” and site-specific cancer SIRs also were computed for 6 classifications of PID, which grouped individual PID entities with related pathophysiology,7  as well as for the most common individual PID conditions. The International Union of Immunologic Societies PID classification includes “predominantly antibody deficiencies,” “complement deficiencies,” “combined T-cell and B-cell immunodeficiencies,” “other well-defined immunodeficiency syndromes,” “congenital defects of phagocyte number, function, or both,” and “diseases of immune dysregulation.”7  The following individual conditions, immunoglobulin G (IgG) subclass deficiency with or without immunoglobulin A (IgA) deficiency, specific defect of IgG, and all isolated IgG subclass deficiency (including isotypes 1-4), were combined into a single classification, “IgG subclass deficiency” for analysis.

Incidence rate ratios

To further explore cancer risk with respect to type of PID, a within-cohort analysis was conducted for NHL, the most common cancer in the cohort. Multivariate Poisson regression was used to calculate incidence rate ratios (IRRs) with 95% CIs for selected PID groupings with adjustment for 5-year age group (time-dependent) and sex. All data analyses were performed with the use of STATA version 10.1 (StataCorp LP).

The study cohort consisted of 1132 patients, 53% of whom were male (Table 1).7  The median age at ASCIA registration was 25 years (range, newborn to 95 years) and the mean duration of follow-up was 16 years (SD, 5.4 years). A total of 111 (9.8%) deaths were observed during follow-up. Most patients (78%) were classified as having a “predominantly antibody deficiency” (Table 1). CVID was the most common entity (n = 416), followed by IgG subclass deficiency with or without IgA deficiency (n = 215), and there were substantially fewer than 100 patients for most other entities (supplemental Table 1, available on the Blood Web site; see the Supplemental Materials link at the top of the online article), limiting our ability to make direct comparisons.

Table 1

Characteristics of the Australian PID cohort

CharacteristicNo. of patients (%)Person-years follow-up for cancer
TotalMean (SD)
Total 1132 (100) 18 055 16.0 (5.4) 
Sex    
    Male 604 (53.3) 9219 15.3 (5.6) 
    Female 528 (46.7) 8836 16.7 (5.0) 
PID classification*    
    Predominantly antibody deficiencies 881 (77.8) 14 313 16.2 (5.0) 
    Complement deficiencies 78 (6.9) 1298 16.6 (4.8) 
    Combined T-cell and B-cell immunodeficiencies 54 (4.8) 632 11.7 (7.2) 
    Other well-defined immunodeficiency syndromes 66 (5.8) 988 15.0 (6.9) 
    Congenital defects of phagocyte number, function, or both 39 (3.5) 602 15.4 (4.6) 
    Diseases of immune dysregulation 14 (1.2) 222 15.9 (4.5) 
Age at follow-up for cancer, y    
    0-9 552 (48.8) 7748 14.0 (5.8) 
    10-19 108 (9.5) 1963 18.2 (4.2) 
    20-29 133 (11.8) 2490 18.7 (4.5) 
    30-39 125 (11.0) 2240 17.9 (4.5) 
    40-49 102 (9.0) 1697 16.6 (3.4) 
    50-59 75 (6.6) 1313 17.5 (3.8) 
    60 and older 37 (3.3) 604 16.3 (3.0) 
CharacteristicNo. of patients (%)Person-years follow-up for cancer
TotalMean (SD)
Total 1132 (100) 18 055 16.0 (5.4) 
Sex    
    Male 604 (53.3) 9219 15.3 (5.6) 
    Female 528 (46.7) 8836 16.7 (5.0) 
PID classification*    
    Predominantly antibody deficiencies 881 (77.8) 14 313 16.2 (5.0) 
    Complement deficiencies 78 (6.9) 1298 16.6 (4.8) 
    Combined T-cell and B-cell immunodeficiencies 54 (4.8) 632 11.7 (7.2) 
    Other well-defined immunodeficiency syndromes 66 (5.8) 988 15.0 (6.9) 
    Congenital defects of phagocyte number, function, or both 39 (3.5) 602 15.4 (4.6) 
    Diseases of immune dysregulation 14 (1.2) 222 15.9 (4.5) 
Age at follow-up for cancer, y    
    0-9 552 (48.8) 7748 14.0 (5.8) 
    10-19 108 (9.5) 1963 18.2 (4.2) 
    20-29 133 (11.8) 2490 18.7 (4.5) 
    30-39 125 (11.0) 2240 17.9 (4.5) 
    40-49 102 (9.0) 1697 16.6 (3.4) 
    50-59 75 (6.6) 1313 17.5 (3.8) 
    60 and older 37 (3.3) 604 16.3 (3.0) 

PID indicates primary immune deficiency; and SD, standard deviation.

*

As classified by the International Union of Immunological Societies Primary Immunodeficiency Diseases Classification Committee.7 

Standardized incidence ratios

All PIDs combined.

Linkage identified a total of 58 cancers (5.7%), including 55 first and 3 second primary cancers. SIRs were significantly elevated for all cancers combined (SIR 1.60), cancer of the thymus gland (SIR 67.3), NHL (SIR 8.82), stomach cancer (SIR 6.10), and leukemia (SIR 5.36; Table 2).23  There were no cases of Kaposi sarcoma nor any oral cavity/oropharyngeal, anogenital, or brain cancers. No cancers occurred at significantly reduced rates relative to the general population.

Table 2

SIRs for cancer in people with PID in Australia

Cancer siteICD-10/ICDO-3 codes*OESIR (95% CI)
Lip C00 0.51 0-7.26 
Oral cavity, oropharynx C01, C02, C03-C06, C09, C10 0.44 0-8.33 
Stomach C16 0.49 6.10 (1.26-17.8) 
Colon C18 2.99 1.34 (0.36-3.43) 
Anus C21 0.10 0-38.0 
Pancreas C25 0.39 2.55 (0.06-14.2) 
Trachea, bronchus, lung C33-C34 1.97 1.02 (0.12-3.67) 
Thymus gland C37 0.03 67.3 (8.15-243) 
Melanoma C43 4.95 0.81 (0.22-2.07) 
Breast (females only) C50 12 7.66 1.57 (0.81-2.74) 
Vulva, vagina, cervix uteri C51-C53 0.79 0-4.67 
Ovary C56 0.57 1.74 (0.04-9.70) 
Penis C60 0.02 0-167 
Prostate C61 3.42 0.88 (0.18-2.57) 
Bladder C67 0.75 3.99 (0.82-11.7) 
Brain C71 0.46 0-8.02 
Thyroid gland C73 0.75 1.34 (0.03-7.45) 
Adrenal gland C74 0.04 26.3 (0.67-147) 
Hodgkin lymphoma ICDO-3 9650-9677 0.29 3.47 (0.09-19.4) 
Non-Hodgkin lymphoma§ ICDO-3 9591, 9596, 9670-9729, 9761, 9820-9837, 9940, 9948 and 9590 if ICD-10, C82-C85 16 1.81 8.82 (5.04-14.3) 
Leukemia ICDO-3 9800-9989, excluding 9820-9837, 9940, 9948 0.75 5.36 (1.46-13.7) 
All malignant neoplasms C00-C96, excluding C44 58 36.2 1.60 (1.22-2.07) 
Cancer siteICD-10/ICDO-3 codes*OESIR (95% CI)
Lip C00 0.51 0-7.26 
Oral cavity, oropharynx C01, C02, C03-C06, C09, C10 0.44 0-8.33 
Stomach C16 0.49 6.10 (1.26-17.8) 
Colon C18 2.99 1.34 (0.36-3.43) 
Anus C21 0.10 0-38.0 
Pancreas C25 0.39 2.55 (0.06-14.2) 
Trachea, bronchus, lung C33-C34 1.97 1.02 (0.12-3.67) 
Thymus gland C37 0.03 67.3 (8.15-243) 
Melanoma C43 4.95 0.81 (0.22-2.07) 
Breast (females only) C50 12 7.66 1.57 (0.81-2.74) 
Vulva, vagina, cervix uteri C51-C53 0.79 0-4.67 
Ovary C56 0.57 1.74 (0.04-9.70) 
Penis C60 0.02 0-167 
Prostate C61 3.42 0.88 (0.18-2.57) 
Bladder C67 0.75 3.99 (0.82-11.7) 
Brain C71 0.46 0-8.02 
Thyroid gland C73 0.75 1.34 (0.03-7.45) 
Adrenal gland C74 0.04 26.3 (0.67-147) 
Hodgkin lymphoma ICDO-3 9650-9677 0.29 3.47 (0.09-19.4) 
Non-Hodgkin lymphoma§ ICDO-3 9591, 9596, 9670-9729, 9761, 9820-9837, 9940, 9948 and 9590 if ICD-10, C82-C85 16 1.81 8.82 (5.04-14.3) 
Leukemia ICDO-3 9800-9989, excluding 9820-9837, 9940, 9948 0.75 5.36 (1.46-13.7) 
All malignant neoplasms C00-C96, excluding C44 58 36.2 1.60 (1.22-2.07) 

95% CI indicates 95% confidence interval; E, expected number of cases; ICD, International Classification of Diseases; ICDO, International Classification of Diseases for Oncology; NHL, non-Hodgkin lymphoma; O, observed number of cases; PID, primary immune deficiency; and SIR, standardized incidence ratio.

*

Lymphoid and hematopoietic neoplasms were classified according to current guidelines for epidemiologic studies23  and include 2 cases with ICDO-3 9960 morphology and ICD-10 D47 topography.

One-tail, 97.5% CI instead of 95% CI because of zero observations.

Statistical significance.

§

Diffuse large B-cell lymphoma (n = 1), follicular lymphoma (n = 3), Burkitt lymphoma/leukemia (n = 1), small lymphocytic lymphoma (n = 1), extranodal marginal zone lymphoma type (n = 1; body site location not specified in national cancer registry records), peripheral T-cell lymphoma (n = 1) unclassified, cutaneous T-cell lymphoma unclassified (n = 1), Waldenström macroglobulinemia (n = 1), NHL unclassified (n = 6).

Chronic myeloproliferative leukemia (n = 2), acute myeloid leukemia (n = 1), and myeloid neoplasms unclassified (n = 1).

“All cancer” and site-specific SIRs were similar for men and women, with the exception of thymoma, which occurred in men only (Table 3). The SIRs for “all cancer” and NHL were significantly increased in both children and adults (Table 4).

Table 3

Site-specific and overall cancer risk for men and women with PID

Cancer siteOESIR (95% CI)
Male, n = 604    
    All malignant neoplasms 23 14.0 1.64 (1.04-2.46)* 
    NHL 0.87 9.22 (3.98-18.2)* 
    Leukemia 0.35 5.77 (0.70-20.9) 
    Stomach 0.26 7.57 (0.92-27.3) 
    Thymus 0.02 114 (13.8-412)* 
Female, n = 528    
    All malignant neoplasms 35 22.2 1.58 (1.10-2.19)* 
    NHL 0.95 8.46 (3.65-16.7)* 
    Leukemia 0.40 5.01 (0.61-18.1) 
    Stomach 0.23 4.40 (0.11-24.5) 
    Thymus 0.01 0-303 
Cancer siteOESIR (95% CI)
Male, n = 604    
    All malignant neoplasms 23 14.0 1.64 (1.04-2.46)* 
    NHL 0.87 9.22 (3.98-18.2)* 
    Leukemia 0.35 5.77 (0.70-20.9) 
    Stomach 0.26 7.57 (0.92-27.3) 
    Thymus 0.02 114 (13.8-412)* 
Female, n = 528    
    All malignant neoplasms 35 22.2 1.58 (1.10-2.19)* 
    NHL 0.95 8.46 (3.65-16.7)* 
    Leukemia 0.40 5.01 (0.61-18.1) 
    Stomach 0.23 4.40 (0.11-24.5) 
    Thymus 0.01 0-303 

95% CI indicates 95% confidence interval; E, expected number of cases; NHL, non-Hodgkin lymphoma; O, observed number of cases; PID, primary immune deficiency; and SIR, standardized incidence ratio.

*

Statistical significance.

C00-C96, excluding C44.

One-tail, 97.5% CI instead of 95% CI because of zero observations.

Table 4

Site-specific and overall cancer risk for children and adults with PID

Cancer siteOESIR (95% CI)
Children (< 16 y; n = 613)    
    All malignant neoplasms 0.64 6.21 (1.69-15.9)* 
    NHL 0.20 9.78 (1.18-35.3)* 
    Leukemia 0.04 24.6 (0.62-137) 
Adults (≥ 16 y; n = 850)    
    All malignant neoplasms 54 35.6 1.52 (1.14-1.98)* 
    NHL 14 1.61 8.70 (4.76-14.6)* 
    Leukemia 0.71 4.26 (0.88-12.4) 
Cancer siteOESIR (95% CI)
Children (< 16 y; n = 613)    
    All malignant neoplasms 0.64 6.21 (1.69-15.9)* 
    NHL 0.20 9.78 (1.18-35.3)* 
    Leukemia 0.04 24.6 (0.62-137) 
Adults (≥ 16 y; n = 850)    
    All malignant neoplasms 54 35.6 1.52 (1.14-1.98)* 
    NHL 14 1.61 8.70 (4.76-14.6)* 
    Leukemia 0.71 4.26 (0.88-12.4) 

95% CI indicates 95% confidence interval; E, expected number of cases; NHL, non-Hodgkin lymphoma; O, observed number of cases; PID, primary immune deficiency; and SIR, standardized incidence ratio.

*

Statistical significance.

C00-C96, excluding C44.

Major PID classifications.

SIRs for “all cancer” and for NHL were significantly increased for patients with “predominantly antibody deficiencies” and “other well-defined immunodeficiency syndromes” (Table 5). The SIR for leukemia was significantly increased for patients with “diseases of immune dysregulation.” No other site-specific SIRs were significantly increased for other PID classifications.

Table 5

Site-specific and overall risk of cancer for the major PID classifications

PID classification/cancer siteOESIR (95% CI)
Predominantly antibody deficiencies, n = 881    
    All malignant neoplasms* 53 32.9 1.61 (1.21-2.11) 
    NHL 13 1.60 8.13 (4.33-13.9) 
    Leukemia 0.67 4.50 (0.93-13.2) 
Complement deficiencies, n = 78    
    All malignant neoplasms* 2.13 0.47 (0.01-2.62) 
    NHL§ 0.11 9.42 (0.24-52.5) 
    Leukemia 0.04 0-92.3 
Combined T-cell and B-cell immunodeficiencies, n = 54    
    All malignant neoplasms* 0.32 0-11.7 
    NHL 0.03 0-117 
    Leukemia 0.01 0-395 
Other well-defined immunodeficiency syndromes, n = 66    
    All malignant neoplasms* 0.23 13.0 (2.69-38.1) 
    NHL 0.03 62.1 (7.51-224) 
    Leukemia 0.01 0-376 
Congenital defects of phagocyte number, function or both, n = 39    
    All malignant neoplasms* 0.48 0-7.69 
    NHL 0.03 0-114 
    Leukemia 0.02 0-227 
Diseases of immune dysregulation, n = 14    
    All malignant neoplasms* 0.23 4.40 (0.11-24.5) 
    NHL 0.01 0-281 
    Leukemia 0.004 238 (6.03-1326) 
PID classification/cancer siteOESIR (95% CI)
Predominantly antibody deficiencies, n = 881    
    All malignant neoplasms* 53 32.9 1.61 (1.21-2.11) 
    NHL 13 1.60 8.13 (4.33-13.9) 
    Leukemia 0.67 4.50 (0.93-13.2) 
Complement deficiencies, n = 78    
    All malignant neoplasms* 2.13 0.47 (0.01-2.62) 
    NHL§ 0.11 9.42 (0.24-52.5) 
    Leukemia 0.04 0-92.3 
Combined T-cell and B-cell immunodeficiencies, n = 54    
    All malignant neoplasms* 0.32 0-11.7 
    NHL 0.03 0-117 
    Leukemia 0.01 0-395 
Other well-defined immunodeficiency syndromes, n = 66    
    All malignant neoplasms* 0.23 13.0 (2.69-38.1) 
    NHL 0.03 62.1 (7.51-224) 
    Leukemia 0.01 0-376 
Congenital defects of phagocyte number, function or both, n = 39    
    All malignant neoplasms* 0.48 0-7.69 
    NHL 0.03 0-114 
    Leukemia 0.02 0-227 
Diseases of immune dysregulation, n = 14    
    All malignant neoplasms* 0.23 4.40 (0.11-24.5) 
    NHL 0.01 0-281 
    Leukemia 0.004 238 (6.03-1326) 

95% CI indicates 95% confidence interval; E, expected number of cases; NHL, non-Hodgkin lymphoma; O, observed number of cases; PID, primary immune deficiency; and SIR, standardized incidence ratio.

*

C00-C96, excluding C44.

Statistical significance.

Diffuse large B-cell lymphoma (n = 1), follicular lymphoma (n = 2), Burkitt lymphoma/leukemia (n = 1), small lymphocytic lymphoma (n = 1), extranodal marginal zone lymphoma type (n = 1), peripheral T-cell lymphoma (n = 1) unclassified, cutaneous T-cell lymphoma unclassified (n = 1), Waldenström macroglobulinemia (n = 1), and NHL unclassified (n = 4).

§

Diffuse large B-cell lymphoma (n = 1).

Follicular lymphoma (n = 1), NHL unclassified (n = 1).

One-tail, 97.5% CI instead of 95% CI because of zero observation.

Individual PID conditions.

SIRs for “all cancer” were significantly increased in patients with CVID (n = 416) and AT (n = 10; Table 6). In patients with CVID, SIRs also were significantly increased for NHL and cancers of the breast (females) and thymus. Both thymus gland cancers were diagnosed in male subjects (aged 48 and 53 years), and both were thymomas. The SIR for stomach cancer was elevated on the basis of 2 cases; a diffuse adenocarcinoma in a 65-year-old subject and a carcinoma of unspecified morphology in a 56-year-old subject. In patients with AT, the SIR for NHL was significantly increased on the basis of a single case.

Table 6

Site-specific and overall cancer risk for the most common individual PID conditions

PID condition/cancer siteOESIR (95% CI)
Common variable immune deficiency, n = 416    
    All malignant neoplasms* 38 19.6 1.94 (1.37-2.67) 
    NHL 11 0.91 12.1 (6.03-21.6) 
    Leukemia 0.40 2.49 (0.06-13.9) 
    Stomach 0.28 7.23 (0.88-26.1) 
    Thymus 0.01 146 (17.7-528) 
    Breast (female only) 4.03 2.24 (1.02-4.24) 
IgG subclass deficiency, n = 244    
    All malignant neoplasms* 11 8.83 1.32 (0.66-2.36) 
    Leukemia 0.15 13.2 (1.60-47.6) 
    Breast (female only) 2.10 1.43 (0.29-4.17) 
Selective IgA deficiencies, n = 90    
    All malignant neoplasms* 3.58 0-1.03 
X-linked agammaglobulinemia, n = 62    
    All malignant neoplasms* 0.32 3.09 (0.08-17.2) 
    Stomach 0.004 236 (5.97-1315) 
Ataxia-telangiectasia, n = 10    
    All malignant neoplasms* 0.05 41.2 (4.99-149) 
    NHL§ 0.006 165 (4.19-922) 
PID condition/cancer siteOESIR (95% CI)
Common variable immune deficiency, n = 416    
    All malignant neoplasms* 38 19.6 1.94 (1.37-2.67) 
    NHL 11 0.91 12.1 (6.03-21.6) 
    Leukemia 0.40 2.49 (0.06-13.9) 
    Stomach 0.28 7.23 (0.88-26.1) 
    Thymus 0.01 146 (17.7-528) 
    Breast (female only) 4.03 2.24 (1.02-4.24) 
IgG subclass deficiency, n = 244    
    All malignant neoplasms* 11 8.83 1.32 (0.66-2.36) 
    Leukemia 0.15 13.2 (1.60-47.6) 
    Breast (female only) 2.10 1.43 (0.29-4.17) 
Selective IgA deficiencies, n = 90    
    All malignant neoplasms* 3.58 0-1.03 
X-linked agammaglobulinemia, n = 62    
    All malignant neoplasms* 0.32 3.09 (0.08-17.2) 
    Stomach 0.004 236 (5.97-1315) 
Ataxia-telangiectasia, n = 10    
    All malignant neoplasms* 0.05 41.2 (4.99-149) 
    NHL§ 0.006 165 (4.19-922) 

95% CI indicates 95% confidence interval; E, expected number of cases; IgA, immunoglobulin A; IgG, immunoglobulin G; NHL, non-Hodgkin lymphoma; O, observed number of cases; PID, primary immune deficiency; and SIR, standardized incidence ratio.

*

C00-C96, excluding C44.

Statistical significance.

Diffuse large B-cell lymphoma (n = 1), follicular lymphoma (n = 2), Burkitt lymphoma/leukemia (n = 1), small lymphocytic lymphoma (n = 1), extranodal marginal zone lymphoma type (n = 1), peripheral T-cell lymphoma (n = 1) unclassified, Waldenström macroglobulinemia (n = 1), and NHL unclassified (n = 3).

§

NHL unclassified (n = 1).

One-tail, 97.5% CI instead of 95% CI because of zero observation.

In patients with IgG subclass deficiency (n = 244), the SIR for leukemia was significantly increased on the basis of 2 cases. There were no cancers diagnosed in patients with selective IgA deficiency. In patients with X-linked agammaglobulinemia (n = 62), the SIR for stomach cancer was significantly increased on the basis of a single case of diffuse adenocarcinoma in a 45-year-old subject.

Incidence rate ratios

The risk of NHL was significantly associated with some PID subtypes after adjustment for age and sex. Compared with predominantly antibody deficiencies excluding CVID, CVID was associated with a 5-fold increased risk (IRR 5.75; 95% CI 1.25-26.5), “other well-defined immunodeficiency syndromes” was associated with a 9-fold increased risk (IRR 9.23; 95% CI 1.23-69.0), and all other PID subtypes combined showed no excess risk (IRR 1.52; 95% CI 0.14-16.8).

This national, population-based cohort study identified a modest excess risk of any cancer and a strong excess risk of a small number of cancers (NHL, stomach, thymus, and leukemia) in patients with PID relative to the general population. Within the statistical power afforded by the study, the data suggest 2 novel insights. First, PID characterized predominantly by antibody deficiency may be associated with a narrower range of solid cancers than predominantly T-cell deficiency after solid organ transplantation or in HIV infection.1  Second, the excess cancer risk may be confined to certain forms of immunodeficiency within PID, and further, to specific disease entities within those broad phenotypes. This study demonstrates the future potential of PID, with its increasingly well characterized genetic basis and forms of immune deficiency and increasing life expectancy, to contribute to our understanding of the role of immune function in cancer control.

Although there are no previously published estimates of cancer risk relative to the general population for the spectrum of PID disease, an excess risk of NHL is well-established.25,26  We found an 8-fold increased risk for NHL for all forms of PID combined; however, the misdiagnosis of lymphoma as PID cannot be excluded. NHL risk was also significantly increased for the PID classifications “predominantly antibody deficiencies” and “other well-defined immunodeficiency syndromes.” With respect to individual PID entities, the SIR for NHL was significantly increased for CVID but not for other forms of predominantly antibody deficiency. This finding is consistent with previous studies, in particular a smaller, prospective population-based study that observed 3 cases of NHL in CVID (SIR 11.1, 95% CI 2.3-32.5) and one case of NHL in IgA deficiency (SIR 2.6, 95% CI 0.1-14.3).11  Notably, these and our population-based SIR estimates are appreciably lower than those obtained for smaller CVID cohorts (n = 3778 and n = 98)9 using hospital-based cancer ascertainment, where estimates of 30- and 259-fold excess risk of NHL have been reported.

Despite including only 10 patients with AT, we observed a significantly increased relative risk of NHL, which is consistent with previous, good-quality evidence from larger AT cohorts.10,13  Apart from cartilage hair hypoplasia,12  the risk of cancer relative to the general population has not been previously quantified for the remaining PID classifications or PID entities. Although our findings support variation in NHL risk by the form of primary immunodeficiency, we had insufficient statistical power to reliably estimate NHL incidence for the rarer PID subtypes.

Lymphomas of B-cell origin appeared to predominate, and most cases were diagnosed in adulthood. Epstein-Barr virus (EBV) infection causally is associated with NHL in immunocompromised hosts27  as a result of depleted EBV-specific CD8+ cytotoxic T cells.28,29  Thus, PIDs with T-cell deficiency are expected to be the most susceptible to EBV-related lymphomas. However, specific genetic defects, such as defective DNA repair in AT30  and impaired NK cell–mediated cytotoxicity in X-linked lymphoproliferative disease,31  also are believed to play a role in lymphomagenesis. Our within-cohort analysis suggests that the form of functional immune impairment in CVID and “other well-defined immunodeficiency syndromes” is associated with a significantly greater risk of NHL relative to all other predominantly antibody deficiencies combined.

Our risk estimate for stomach cancer for all PID (SIR 6.10) is similar to the only previous population-based estimate for CVID and IgA deficiency combined (SIR 7.5; n = 562), and is appreciably lower than a hospital-based estimate for CVID (47-fold).8  The increased risk of stomach cancer suggests that local gastrointestinal effects associated with PID, such as the decreased production of gastric IgA and hydrochloric acid, may facilitate Helicobacter pylori colonization and gastric inflammation and promote carcinogenesis. Although there is mixed support for such a pathogenic mechanism,32-35  and the role for cofactors such as alterations in the p53 gene are yet to be clarified,36  these data support the regular use of diagnostic tests and treatment of H pylori infection in adults with PID, together with endoscopic follow-up of those with premalignant gastric lesions.37 

We observed a large excess risk for thymoma on the basis of 2 cases occurring in patients with CVID. Goods syndrome, or “thymoma with immunodeficiency,” is a rare form of predominantly antibody deficiency characterized by the occurrence of adult-onset hypogammaglobulinemia either before or after the diagnosis of thymoma.38  Although regarded by some as a subset of CVID, it is now classified as a separate entity.

We found a significantly increased risk of leukemia for all PID, “diseases of immune dysregulation,” and “IgG subclass deficiency.” Despite the strong previous evidence, we did not observe an excess risk of leukemia in AT.10,13  Our observation of an increased relative risk of breast cancer in CVID is novel, apart from recent case reports in 2 young women.39  Although our finding is based on 9 incident breast cancer cases, chance cannot be excluded as an explanation. This finding is worthy of further investigation as mothers of children with AT appear to be at increased risk10  and no excess risk is observed in acquired and iatrogenic immunodeficiency.1 

The evidence accumulated to-date suggests that the cancer profile in PID may differ from that observed in iatrogenic and acquired immunodeficiency, where a wide range of solid cancers with an infectious etiology occur at excess risk.1  Of the many solid cancers with an established infectious cause,40  only stomach cancer appears to occur at a significantly higher rate in PID.8-13  The size of our cohort and the comparative rarity of infection-related cancers such as Kaposi sarcoma and anogenital and orpharyngeal cancers cannot be ruled out, but there are also other possible explanations. First, the cancer profile may reflect a lower rate of infection by the causally associated sexually acquired infectious agents40  in this patient group. Second, in comparison with HIV-related and iatrogenic immunosuppression, primary antibody deficiency disorders may occur in the context of relatively preserved T-cell effector function, and T-cell dysfunction may carry the majority of the attributable risk. For example, in HIV, Kaposi sarcoma risk is strongly inversely associated with CD4+ T-cell count.41,42  In CVID, however, only a small subset (< 10%) of patients appear to have very low CD4 counts.43  A final possibility is that Ig-replacement therapy, used in 71% of the cohort,15  is associated with a reduced risk of cancer in PID. If true, such an effect would be consistent with the reduction in risk of some cancers after the use of highly active antiretroviral therapy in HIV17  and after the removal of iatrogenic immunosuppression in kidney transplant recipients.44  It also accords with a case report of regression of Kaposi sarcoma in a HIV patient after IVIG therapy.45 

This study used one of the world's largest national PID registers and national death and cancer notifications to enable unbiased death and cancer ascertainment relative to the general population. Furthermore, it is the first study to examine site-specific cancer risk across the spectrum of PID subtypes, allowing comparisons between some PID conditions with related pathogenesis. Despite these strengths, several limitations must be considered. Although large by comparison with most previous studies with population-level comparison data, the cohort size and the observed number of cancers are insufficient for comprehensive risk factor modeling and robust comparisons between individual PID conditions and with other forms of immune impairment. Furthermore, in common with other registries of this kind, the ASCIA PID Registry is affected by under-reporting, achieving registration of an estimated 34% to 37% of its target population,15  and potentially misclassification error because of misdiagnosis.7  In particular, it is possible that patients originally diagnosed with CVID may be subsequently diagnosed with X-linked lymphoproliferative disease or CD40L deficiency, rare conditions known to be associated with cancer.30,46 

In addition, our analyses were determined by the assumption that immune dysfunction was present for up to 15 years before ASCIA registration. Although our approach accords with the congenital basis of these conditions, it would over-estimate the PY at risk for cancer if adult-onset disorders arose by somatic genetic error later in life. Nevertheless, our approach does offset the diagnostic delay typically experienced for PID, particularly for conditions such as CVID that are usually diagnosed in adulthood.47  However, although survival adjustment was performed to account for the retrospective period of follow-up, survival bias may not have been completely eliminated, which would also over-estimate the PY at risk of cancer and weaken the PID-cancer association. Despite these limitations, our risk estimates for CVID and IgA deficiency are of similar magnitude to those obtained for a smaller cohort on the basis of a well-defined diagnostic criteria and with prospective follow-up for cancer.11 

Although there is long-standing evidence of a strong link between PID and cancer, the association has been understudied. As the life expectancy of people with PID increases because of improvements in the surveillance, prevention, and treatment of chronic infections, the occurrence of cancer is expected to increase. The population-level collection of detailed information on the extent and type of functional immune impairment, in addition to the type and duration of any immune reconstitution therapy or potentially curative treatment such as hematopoietic stem cell transplantation, has the potential to inform patient management. In addition, large-scale comparisons of the long-term cancer risk in different types of PID and other forms of immune dysfunction may give insight into the immunologic and genetic determinants of specific cancers. Such information would inform the development of models of carcinogenesis and thus cancer prevention strategies in both immune-deficient and non–immune-deficient populations.

An Inside Blood analysis of this article appears at the front of this issue.

The online version of this article contains a data supplement.

The publication costs of this article were defrayed in part by page charge payment. Therefore, and solely to indicate this fact, this article is hereby marked “advertisement” in accordance with 18 USC section 1734.

We gratefully acknowledge the ASCIA members that contributed to and maintained the database. The interpretation and reporting of these data are the responsibility of the authors and in no way should be seen as official policy or interpretation of the ASCIA PID Registry. We are also grateful to the staff of the state and territory cancer registries for the use of their data. We acknowledge the Australian Institute of Health and Welfare for conducting the data linkage for this study.

This work was supported by grants from the Cancer Institute NSW (07/CDF/1-38 to C.M.V. and 06/RSA/1-28 to M.T.v.L.). The ASCIA PID Registry is supported by unrestricted grants from CSL Bioplasma Ltd and Octapharma Ltd.

Contribution: C.M.V., M.T.v.L., A.E.G., and S.R. designed the research; L.M. and M.T.v.L. performed statistical analysis; C.M.V., L.M., and S.R. drafted the manuscript; and M.T.v.L., P.K., and A.E.G. critically reviewed the manuscript.

Conflict-of-interest disclosure: The authors declare no competing financial interests.

Correspondence: Dr Claire M. Vajdic, PhD, Lowy Cancer Research Centre, Level 4 Faculty of Medicine, University of New South Wales, Sydney NSW 2052, Australia; e-mail: [email protected].

1
Grulich
 
AE
van Leeuwen
 
MT
Falster
 
MO
Vajdic
 
CM
Incidence of cancers in people with HIV/AIDS compared with immunosuppressed transplant recipients: a meta-analysis.
Lancet
2007
, vol. 
370
 
9581
(pg. 
59
-
67
)
2
van Leeuwen
 
MT
Grulich
 
AE
Webster
 
AC
, et al. 
Immunosuppression and other risk factors for early and late non-Hodgkin lymphoma after kidney transplantation.
Blood
2009
, vol. 
114
 
3
(pg. 
630
-
637
)
3
Clifford
 
GM
Rickenbach
 
M
Lise
 
M
, et al. 
Hodgkin lymphoma in the Swiss HIV Cohort Study.
Blood
2009
, vol. 
113
 
23
(pg. 
5737
-
5742
)
4
Vajdic
 
CM
van Leeuwen
 
MT
Webster
 
AC
, et al. 
Cutaneous melanoma is related to immune suppression in kidney transplant recipients.
Cancer Epidemiol Biomarkers Prev
2009
, vol. 
18
 
8
(pg. 
2297
-
2303
)
5
Engels
 
EA
Pfeiffer
 
RM
Landgren
 
O
Moore
 
RD
Immunologic and virologic predictors of AIDS-related non-Hodgkin lymphoma in the highly active antiretroviral therapy era.
J Acquir Immune Defic Syndr
2010
, vol. 
54
 
1
(pg. 
78
-
84
)
6
Landgren
 
O
Goedert
 
JJ
Rabkin
 
CS
, et al. 
Circulating serum free light chains as predictive markers of AIDS-related lymphoma.
J Clin Oncol
2010
, vol. 
28
 
5
(pg. 
773
-
779
)
7
Notarangelo
 
LD
Fischer
 
A
Geha
 
RS
, et al. 
Primary immunodeficiencies: 2009 update.
J Allergy Clin Immunol
2009
, vol. 
124
 
6
(pg. 
1161
-
1178
)
8
Kinlen
 
LJ
Webster
 
AD
Bird
 
AG
, et al. 
Prospective study of cancer in patients with hypogammaglobulinaemia.
Lancet
1985
, vol. 
1
 
8423
(pg. 
263
-
266
)
9
Cunningham-Rundles
 
C
Siegal
 
FP
Cunningham-Rundles
 
S
Lieberman
 
P
Incidence of cancer in 98 patients with common varied immunodeficiency.
J Clin Immunol
1987
, vol. 
7
 
4
(pg. 
294
-
299
)
10
Olsen
 
JH
Hahnemann
 
JM
Borresen-Dale
 
AL
, et al. 
Cancer in patients with ataxia-telangiectasia and in their relatives in the Nordic countries.
J Natl Cancer Inst
2001
, vol. 
93
 
2
(pg. 
121
-
127
)
11
Mellemkjaer
 
L
Hammarstrom
 
L
Andersen
 
V
, et al. 
Cancer risk among patients with IgA deficiency or common variable immunodeficiency and their relatives: a combined Danish and Swedish study.
Clin Exp Immunol
2002
, vol. 
130
 
3
(pg. 
495
-
500
)
12
Taskinen
 
M
Ranki
 
A
Pukkala
 
E
Jeskanen
 
L
Kaitila
 
I
Makitie
 
O
Extended follow-up of the Finnish cartilage-hair hypoplasia cohort confirms high incidence of non-Hodgkin lymphoma and basal cell carcinoma.
Am J Med Genet A
2008
, vol. 
146A
 
18
(pg. 
2370
-
2375
)
13
Morrell
 
D
Cromartie
 
E
Swift
 
M
Mortality and cancer incidence in 263 patients with ataxia-telangiectasia.
J Natl Cancer Inst
1986
, vol. 
77
 
1
(pg. 
89
-
92
)
14
Baumgart
 
KW
Britton
 
WJ
Kemp
 
A
French
 
M
Roberton
 
D
The spectrum of primary immunodeficiency disorders in Australia.
J Allergy Clin Immunol
1997
, vol. 
100
 
3
(pg. 
415
-
423
)
15
Kirkpatrick
 
P
Riminton
 
S
Primary immunodeficiency diseases in Australia and New Zealand.
J Clin Immunol
2007
, vol. 
27
 
5
(pg. 
517
-
524
)
16
Grulich
 
AE
Wan
 
X
Law
 
MG
Coates
 
M
Kaldor
 
JM
Risk of cancer in people with AIDS.
AIDS
1999
, vol. 
13
 
7
(pg. 
839
-
843
)
17
van Leeuwen
 
MT
Vajdic
 
CM
Middleton
 
MG
, et al. 
Continuing declines in some but not all HIV-associated cancers in Australia after widespread use of antiretroviral therapy.
AIDS
2009
, vol. 
23
 
16
(pg. 
2183
-
2190
)
18
Australian Institute of Health and Welfare, Australasian Association of Cancer Registries.
Cancer Survival in Australia, 2001
2001
Canberra, Australian Capital Territory
Australian Institute of Health and Welfare
 
AIHW Cancer Series No. 19
19
South Australian Cancer Registry
Epidemiology of Cancer in South Australia
2000
Adelaide, South Australia
South Australian Cancer Registry
20
Vajdic
 
CM
McDonald
 
SP
McCredie
 
MR
, et al. 
Cancer incidence before and after kidney transplantation.
JAMA
2006
, vol. 
296
 
23
(pg. 
2823
-
2831
)
21
Frisch
 
M
Biggar
 
RJ
Goedert
 
JJ
Human papillomavirus-associated cancers in patients with human immunodeficiency virus infection and acquired immunodeficiency syndrome.
J Natl Cancer Inst
2000
, vol. 
92
 
18
(pg. 
1500
-
1510
)
22
Li
 
Y
Law
 
M
McDonald
 
A
Correll
 
P
Kaldor
 
JM
Grulich
 
AE
Estimation of risk of cancers before occurrence of acquired immunodeficiency syndrome in persons infected with human immunodeficiency virus.
Am J Epidemiol
2002
, vol. 
155
 
2
(pg. 
153
-
158
)
23
Morton
 
LM
Turner
 
JJ
Cerhan
 
JR
, et al. 
Proposed classification of lymphoid neoplasms for epidemiologic research from the Pathology Working Group of the International Lymphoma Epidemiology Consortium (InterLymph).
Blood
2007
, vol. 
110
 
2
(pg. 
695
-
708
)
24
Breslow
 
NE
Day
 
NE
Statistical Methods in Cancer Research. Volume II: The Design and Analysis of Cohort Studies.
IARC Scientific Publications No. 82
1987
Lyon, France
Oxford University Press
25
Filipovich
 
AH
Mathur
 
A
Kamat
 
D
Kersey
 
JH
Shapiro
 
RS
Lymphoproliferative disorders and other tumors complicating immunodeficiencies.
Immunodeficiency
1994
, vol. 
5
 
2
(pg. 
91
-
112
)
26
Cunningham-Rundles
 
C
Cooper
 
DL
Duffy
 
TP
Strauchen
 
J
Lymphomas of mucosal-associated lymphoid tissue in common variable immunodeficiency.
Am J Hematol
2002
, vol. 
69
 
3
(pg. 
171
-
178
)
27
International Agency for Research on Cancer (IARC)
IARC Monographs on the evaluation of carcinogenic risks to humans: Epstein-Barr virus and Kaposi's sarcoma herpesvirus/human herpesvirus 8, Volume 70.
1997
Lyon, France
IARC Press
28
Dolcetti
 
R
B lymphocytes and Epstein-Barr virus: the lesson of post-transplant lymphoproliferative disorders.
Autoimmun Rev
2007
, vol. 
7
 
2
(pg. 
96
-
101
)
29
Pietersma
 
F
Piriou
 
E
van Baarle
 
D
Immune surveillance of EBV-infected B cells and the development of non-Hodgkin lymphomas in immunocompromised patients.
Leuk Lymphoma
2008
, vol. 
49
 
6
(pg. 
1028
-
1041
)
30
Eyfjord
 
JE
Bodvarsdottir
 
SK
Genomic instability and cancer: networks involved in response to DNA damage.
Mutat Res
2005
, vol. 
592
 
1–2
(pg. 
18
-
28
)
31
Parolini
 
S
Bottino
 
C
Falco
 
M
, et al. 
X-linked lymphoproliferative disease. 2B4 molecules displaying inhibitory rather than activating function are responsible for the inability of natural killer cells to kill Epstein-Barr virus–infected cells.
J Exp Med
2000
, vol. 
192
 
3
(pg. 
337
-
346
)
32
Bogstedt
 
AK
Nava
 
S
Wadstrom
 
T
Hammarstrom
 
L
Helicobacter pylori infections in IgA deficiency: lack of role for the secretory immune system.
Clin Exp Immunol
1996
, vol. 
105
 
2
(pg. 
202
-
204
)
33
Akhiani
 
AA
The role of type-specific antibodies in colonization and infection by Helicobacter pylori.
Curr Opin Infect Dis
2005
, vol. 
18
 
3
(pg. 
223
-
227
)
34
Knekt
 
P
Teppo
 
L
Aromaa
 
A
Rissanen
 
H
Kosunen
 
TU
Helicobacter pylori IgA and IgG antibodies, serum pepsinogen I and the risk of gastric cancer: changes in the risk with extended follow-up period.
Int J Cancer
2006
, vol. 
119
 
3
(pg. 
702
-
705
)
35
Quiding-Järbrink
 
M
Sundstrom
 
P
Lundgren
 
A
, et al. 
Decreased IgA antibody production in the stomach of gastric adenocarcinoma patients.
Clin Immunol
2009
, vol. 
131
 
3
(pg. 
463
-
471
)
36
Zullo
 
A
Romiti
 
A
Rinaldi
 
V
, et al. 
Gastric pathology in patients with common variable immunodeficiency.
Gut
1999
, vol. 
45
 
1
(pg. 
77
-
81
)
37
Deane
 
S
Selmi
 
C
Naguwa
 
SM
Teuber
 
SS
Gershwin
 
ME
Common variable immunodeficiency: etiological and treatment issues.
Int Arch Allergy Immunol
2009
, vol. 
150
 
4
(pg. 
311
-
324
)
38
Tarr
 
PE
Sneller
 
MC
Mechanic
 
LJ
, et al. 
Infections in patients with immunodeficiency with thymoma (Good syndrome). Report of 5 cases and review of the literature.
Medicine (Baltimore)
2001
, vol. 
80
 
2
(pg. 
123
-
133
)
39
Mehta
 
AC
Faber-Langendoen
 
K
Duggan
 
DB
Common variable immunodeficiency and breast cancer.
Cancer Invest
2004
, vol. 
22
 
1
(pg. 
93
-
96
)
40
Bouvard
 
V
Baan
 
R
Straif
 
K
, et al. 
A review of human carcinogens—Part B: biological agents.
Lancet Oncol
2009
, vol. 
10
 
4
(pg. 
321
-
322
)
41
Clifford
 
GM
Polesel
 
J
Rickenbach
 
M
, et al. 
Cancer risk in the Swiss HIV Cohort Study: associations with immunodeficiency, smoking, and highly active antiretroviral therapy.
J Natl Cancer Inst
2005
, vol. 
97
 
6
(pg. 
425
-
432
)
42
Franceschi
 
S
Maso
 
LD
Rickenbach
 
M
, et al. 
Kaposi sarcoma incidence in the Swiss HIV Cohort Study before and after highly active antiretroviral therapy.
Br J Cancer
2008
, vol. 
99
 
5
(pg. 
800
-
804
)
43
Malphettes
 
M
Gerard
 
L
Carmagnat
 
M
, et al. 
Late-onset combined immune deficiency: a subset of common variable immunodeficiency with severe T cell defect.
Clin Infect Dis
2009
, vol. 
49
 
9
(pg. 
1329
-
1338
)
44
van Leeuwen
 
MT
Webster
 
AC
McCredie
 
MR
, et al. 
Effect of reduced immunosuppression after kidney transplant failure on risk of cancer: population based retrospective cohort study.
BMJ
2010
, vol. 
340
 pg. 
c570
 
45
Carmeli
 
Y
Mevorach
 
D
Kaminski
 
N
Raz
 
E
Regression of Kaposi's sarcoma after intravenous immunoglobulin treatment for polymyositis.
Cancer
1994
, vol. 
73
 
11
(pg. 
2859
-
2861
)
46
Erdos
 
M
Garami
 
M
Rakoczi
 
E
, et al. 
Neuroendocrine carcinoma associated with X-linked hyper-immunoglobulin M syndrome: report of four cases and review of the literature.
Clin Immunol
2008
, vol. 
129
 
3
(pg. 
455
-
461
)
47
Chapel
 
H
Lucas
 
M
Lee
 
M
, et al. 
Common variable immunodeficiency disorders: division into distinct clinical phenotypes.
Blood
2008
, vol. 
112
 
2
(pg. 
277
-
286
)
Sign in via your Institution